- Home
- FLUX vs CVM Comparison
FLUX vs CVM Comparison
Compare FLUX & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FLUX | CVM |
|---|---|---|
| Founded | N/A | 1983 |
| Country | United States | United States |
| Employees | N/A | 44 |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.3M | 21.4M |
| IPO Year | 2019 | 1996 |
Fundamental Metrics
Financial Performance| Metric | FLUX | CVM |
|---|---|---|
| Price | $1.05 | $1.53 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 132.2K | ★ 805.5K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,317,000.00 | $264,033.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $23.01 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 126.25 | 65.45 |
| 52 Week Low | $0.91 | $0.89 |
| 52 Week High | $7.55 | $13.48 |
Technical Indicators
Market Signals| Indicator | FLUX | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 48.18 | 37.27 |
| Support Level | $1.04 | $0.89 |
| Resistance Level | $1.20 | $1.86 |
| Average True Range (ATR) | 0.07 | 0.21 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 72.39 | 65.69 |
Price Performance
Historical ComparisonAbout FLUX Flux Power Holdings Inc.
Flux Power Holdings Inc design, develop, manufacture, and sell a portfolio of lithium-ion energy storage solutions for electrification of a range of industrial commercial sectors which include material handling, airport ground support equipment (GSE), and other commercial and industrial applications. It offers a high-power battery cell management system(BMS). The company's BMS provides three functions to its battery systems which include Cell Balancing, Monitoring, and Error Reporting.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.